한글목차

세계 조진균증 치료제 시장의 미래는 병원 약국, 소매 약국, 온라인 약국 시장에서의 기회로 유망시되고 있습니다. 세계의 조진균증 치료제 시장은 2025-2031년에 CAGR 5.0%로 성장할 것으로 예상되고 있습니다. 이 시장의 주요 촉진요인은 손발톱 무좀의 유병률 상승, 치료 옵션에 대한 의식의 향상, 편리하고 효과적인 치료에 대한 수요 증가입니다.

• Lucintel의 예측에 따르면 유형별로는 내복약이 예측 기간 중 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 소매 약국이 가장 높은 성장이 예상됩니다.
• 지역별로는 북미가 예측 기간 중 가장 높은 성장세를 보일 것으로 예측됩니다.

손발톱 백선 치료제 시장의 새로운 동향

손발톱 백선 치료제 시장은 전 세계에서 곰팡이성 손발톱 감염 치료를 재정의하는 새로운 동향으로 인해 빠르게 변화하고 있습니다. 이러한 추세는 기술 발전, 인식의 향상, 개선되고 편리한 치료에 대한 소비자의 요구가 증가함에 따라 더욱 가속화되고 있습니다. 다음은 손발톱무좀 치료제 시장의 미래 방향을 형성할 5가지 주요 신흥 동향입니다.

• 국소 항진균제 치료의 발전: 조진균증에 대한 국소 치료의 발전으로 부작용이 적고 더 효과적인 약물이 등장하고 있습니다. 에피나코나졸과 타바보롤은 환자들에게 보다 간편하고, 보다 타겟팅된 국소 요법을 제공함으로써 큰 영향을 미친 약물 중 하나입니다. 이러한 국소 치료는 경구용 항진균제의 긴 치료 기간을 대체할 수 있는 치료법으로 인기를 얻고 있습니다. 또한 경구용 항진균제에서 발생할 수 있는 전신 부작용을 피할 수 있으며, 많은 환자들이 선호하는 치료법입니다.
• 레이저와 빛에 의한 치료: 조진균증에 대한 레이저 치료와 빛 치료의 적용은 최근 수년간 빠르게 확산되고 있습니다. 레이저 치료는 빛을 손톱에 침투시켜 곰팡이에 도달하게 하여 환자에게 통증이 없는 치료법입니다. 이러한 치료의 매력은 일반적으로 빠르고 통증이 없습니다는 점입니다. 기존의 항진균제 내복이 부작용으로 인해 견디기 힘든 사람들에게 특히 유리한 치료법입니다. 레이저 치료의 인기 증가는 환자들이 보다 빠르고 효율적인 치료법을 찾고 있으므로 조진균증 치료제 시장의 견인차 역할을 할 것으로 예측됩니다.
• 병용요법: 외용 항진균제와 경구 항진균제를 함께 사용하는 병용요법은 손발톱무좀 치료에 있으며, 인기가 높아지고 있습니다. 병용요법은 다양한 방향에서 곰팡이를 공격하여 치료 효과를 높이기 위해 시행됩니다. 경구용 항진균제와 외용제를 혼합하여 더 깊은 감염을 치료하고 더 철저한 진균 제거가 가능합니다. 이는 보다 빠른 치료 결과와 보다 철저한 치료 요법에 대한 수요 증가에 힘입어 병용요법은 시장에서 중요한 발전으로 자리매김하고 있습니다.
• 환자 중심 치료로의 전환: 손발톱무좀 치료제 시장은 환자의 편의성과 순응도를 높이는 것을 우선시하며, 환자 중심의 치료로 변화하고 있습니다. 새로운 제제는 용량을 줄이거나 요법을 단순화하여 사용하기 쉽도록 처방되고 있습니다. 예를 들어 치료의 복잡성을 제한하기 위해 1회 경구용 정제나 캡슐이 개발되고 있습니다. 또한 환자 친화적인 새로운 패키지와 라벨은 환자 경험의 질을 향상시키고 있습니다. 이러한 추세는 치료 순응도를 극대화하고 환자 결과의 질을 향상시키기 위해 매우 중요합니다.
• R&D 투자 확대: 제약회사들은 조진균증에 대한 새로운 치료법을 개발하기 위해 R&D에 대한 투자를 늘리고 있습니다. 조진균증이 더 널리 알려지면서 보다 효과적인 약물과 다른 치료법, 예를 들어 새로운 항진균제나 혁신적인 약물전달 장비를 개발하려는 기업의 의지가 높아지고 있습니다. 임상 연구 및 임상시험에서는 부작용이 적고, 더 빠르고 철저하게 곰팡이를 제거할 수 있는 새로운 대체 약물에 대한 연구가 진행되고 있습니다. 연구개발비 증가는 손발톱무좀 치료제 시장의 기술 혁신 속도를 촉진할 것으로 보입니다.

국소 치료의 성장, 새로운 레이저 치료, 병용 요법, 환자 중심 접근법으로의 전환, R&D 투자 증가 등 신흥 시장 동향은 손발톱무좀 치료제 시장에 변화를 가져오고 있습니다. 이러한 추세는 보다 효율적이고, 간편하며, 환자 친화적인 치료법에 대한 요구가 증가하고 있음을 보여줍니다. 이러한 신흥 동향이 계속 발전함에 따라 시장은 앞으로 더 많은 혁신과 확장이 예상되며, 이는 환자와 제약사 모두에게 유리하게 작용할 것으로 보입니다.

손발톱 백선 치료제 시장의 최근 동향

손발톱무좀 치료제 시장은 새로운 치료법의 도입, 신약의 승인, 환자의 편의성에 대한 관심 증가로 인해 끊임없이 변화하고 있습니다. 새로운 항진균제의 승인과 대체 치료제의 인기 증가 등 최근 수년간 시장 개발을 결정지은 중요한 동향은 여러 가지가 있습니다. 다음은 손발톱무좀 치료제 시장을 발전시킬 5가지 주요 동향을 소개합니다.

• 새로운 항진균제 승인: 새로운 항진균제의 승인은 손발톱 백선 치료제 시장에 큰 영향을 미치고 있습니다. 에피나코나졸이나 타바보롤과 같은 약물은 기존 약품에 비해 우수한 약품으로 등장했습니다. 이 새로운 약물은 더 효과적일 뿐만 아니라 환자에게 부작용이 적은 치료법을 제공합니다. 이러한 신약이 출시됨에 따라 더 많은 환자들이 안전성 프로파일이 개선되고 더 빠른 결과를 얻을 수 있는 치료법을 선택하게 되면서 시장 성장을 가속하고 있습니다.
• 레이저 치료의 대중화: 레이저 치료는 비침습적이고 효과적이기 때문에 손발톱 백선 치료제 시장에서 점점 더 인기를 얻고 있습니다. 레이저 치료는 경구용 항진균제의 부작용을 싫어하는 환자들에게 선호되는 선택이 되고 있습니다. 피부과 전문의와 족부 전문의의 레이저 치료 사용은 다운타임을 최소화하면서 효과적인 치료를 원하는 환자들에게 대안을 제공하면서 시장을 주도하고 있습니다.
• 병용요법 개발: 경구용 항진균제와 국소용 항진균제를 함께 사용하는 병용요법 개발은 손발톱무좀 치료제 시장의 또 다른 큰 혁신입니다. 이 전략은 다양한 메커니즘으로 곰팡이에 작용하여 보다 종합적으로 감염을 치료하는 것을 목표로 합니다. 병용요법은 임상시험에서 더 효과적인 것으로 입증되어 심각한 조진균증과 만성 조진균증 환자들에게 유력한 선택이 되고 있습니다.
• 처방전 치료에서 벗어나기: 조진균증에 대한 처방전 치료법에서 벗어나려는 움직임이 있습니다. 환자들은 더 편리하고 저렴한 치료법을 원하며, 더 많은 자가 치료를 선택하고 있습니다. 더 많은 환자들이 편리하고 저렴한 치료 옵션으로 OTC 항진균제 스프레이, 파우더, 크림을 선택하고 있습니다. 이러한 추세는 전문적인 치료를 필요로 하지 않는 많은 소비자를 타겟팅하여 시장 성장에 기여하고 있습니다.
• 소아 및 노인 인구의 중요성: 최근 수년간 진균 감염증에 취약한 소아 및 노인 인구의 손발톱 백선 치료에 대한 중요성이 강조되고 있습니다. 인구가 고령화되고 소아 진균 감염이 증가함에 따라 제약사들은 이 그룹에 특화된 보다 안전하고 효과적인 약물을 개발하고 있습니다. 이러한 집중적인 노력은 조진균증에 대한 보다 표적화된 치료를 가능하게 하여 시장 성장의 원동력이 되고 있습니다.

새로운 항진균제의 출시, 레이저 치료의 사용 증가, 병용 치료의 개발, 일반의약품(OTC)물로의 전환, 소아 및 노인 그룹을 대상으로 한 치료 등 모든 주요 동향은 조진균증 치료제 시장의 놀라운 성장에 박차를 가하고 있습니다. 이러한 추세는 또한 더 좋고, 더 편리하고, 더 구체적인 치료에 대한 요구가 증가하고 있으며, 이는 시장의 지속적인 성장과 혁신을 기대할 수 있게 합니다.

목차

제1장 개요

제2장 세계의 조진균증 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 2019-2031년 시장 동향과 예측 분석

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 조진균증 치료제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 조진균증 치료제 시장 : 유형별
  • 구강 내과
  • 외용약
• 세계의 조진균증 치료제 시장 : 용도별
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 2019-2031년 지역별 시장 동향과 예측 분석

• 조진균증 치료제 시장 : 지역별
• 북미의 조진균증 치료제 시장
• 유럽의 조진균증 치료제 시장
• 아시아태평양의 조진균증 치료제 시장
• 기타 지역의 조진균증 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 조진균증 치료제 시장의 성장 기회 : 유형별
  • 세계의 조진균증 치료제 시장의 성장 기회 : 용도별
  • 세계의 조진균증 치료제 시장의 성장 기회 : 지역별
• 세계의 조진균증 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 조진균증 치료제 시장의 생산능력 확대
  • 세계의 조진균증 치료제 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 기업 개요

• Johnson & Johnson
• GSK
• Novartis
• Pfizer
• Bausch Health
• Kaken Pharmaceutical
• Galderma Bayer
• Lumenis
• Moberg Pharma
• Cipla

영문목차

The future of the global onychomycosis drug market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global onychomycosis drug market is expected to grow with a CAGR of 5.0% from 2025 to 2031. The major drivers for this market are the rising prevalence of onychomycosis, the growing awareness of treatment options, and the increasing demand for convenient and effective treatments.

• Lucintel forecasts that, within the type category, oral medicine is expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Onychomycosis Drug Market

The onychomycosis drug market is rapidly changing with emerging trends that are redefining the treatment of fungal nail infections all over the world. The trends are fueled by technological advances, heightened awareness, and a growing need from consumers for improved and more convenient treatments. Following are five important emerging trends in the onychomycosis drug market that are shaping its future direction.

• Progress in Topical Antifungal Therapies: The progress in topical therapies for onychomycosis has seen more effective drugs with fewer side effects. Efinaconazole and tavaborole are among the drugs that have made a great impact, providing localized therapy that is more convenient for patients to apply and more targeted. These topical treatments are becoming more popular as they offer an alternative to the longer treatment times of oral antifungal medication. They also circumvent the systemic side effects that may arise from oral drugs, making them a preferred treatment for most patients.
• Laser and Light-Based Therapies: The application of laser treatment and light therapy for onychomycosis has picked up speed in recent years. Laser therapy involves using light to penetrate through the nail and reach the fungus, offering a painless alternative to patients. Their general quickness and painlessness are the attractions of such treatments. They are particularly advantageous for individuals who cannot tolerate conventional oral antifungals because of side effects. The increasing popularity of laser treatments is likely to help drive the onychomycosis drug market as patients look for quicker and more efficient methods of treatment.
• Combination Therapies: Combination therapies that use both topical and oral antifungal treatments are gaining increasing popularity in treating onychomycosis. Combination therapies are implemented with the goal of enhancing the effectiveness of the treatment by attacking the fungus from diverse directions. Blending oral antifungals with topical medications can assist in treating deeper infections and providing more thorough elimination of the fungus. This is being fueled by greater demand for quicker outcomes and more thorough treatment regimens, positioning combination therapies as a significant development in the marketplace.
• Trend Toward Patient-Focused Therapies: The market for onychomycosis drugs is trending toward more patient-focused therapies, prioritizing enhancing patient convenience and adherence. New formulations are formulated to be easy to use, with fewer dosages or simpler regimens. For instance, single-dose oral tablets and capsules are in development to limit the complexity of treatment. New patient-friendly packages and labels also enhance the quality of the overall patient experience. This trend is critical as it maximizes chances of treatment compliance and improves the quality of outcomes for patients.
• More Investment in Research and Development: Pharmaceuticals are investing more in research and development to formulate new and novel treatments for onychomycosis. Since the disease is becoming more widespread, there is a high degree of motivation among companies to establish more effective medications and other therapeutic options, for example, novel antifungal agents or innovative drug delivery devices. Clinical studies and trials are investigating new alternatives that provide quicker, more thorough fungal elimination with fewer side effects. The growth in R&D spending is likely to drive the rate of innovation in the onychomycosis pharmaceutical market.

Emerging trends like growth in topical treatments, emerging laser therapies, combination therapy, a transition towards patient-centric approaches, and higher investments in research and development are transforming the onychomycosis drug market. These trends depict the increasing need for more efficient, hassle-free, and patient-friendly treatment. As these emerging trends keep developing, the market is likely to witness even more innovation and expansion in the future years, favoring both patients and pharmaceutical manufacturers.

Recent Developments in the Onychomycosis Drug Market

The onychomycosis drug market is constantly changing with new treatments being introduced, novel drug approvals, and a growing emphasis on patient convenience. A number of significant developments have defined the development of the market over recent years, including the approval of new antifungal drugs to increasing popularity of alternative treatments. What follows are five major developments that are propelling the onychomycosis drug market forward.

• New Antifungal Drug Approvals: New antifungal drug approvals have had a tremendous effect on the onychomycosis drug market. Medications such as efinaconazole and tavaborole have been brought forth as superior drugs compared to the traditional ones. Not only are these new drugs more effective, but they also provide patients with fewer side effects treatment options. The availability of these novel drugs has driven growth in the market, as more patients are choosing treatments that provide faster results with improved safety profiles.
• Growing Use of Laser Therapy: Laser therapy has become increasingly popular in the onychomycosis drug market because it is non-invasive and effective. Laser treatments are becoming a favored choice for patients who do not want to experience the possible side effects of oral antifungals. The use of laser treatments by dermatologists and podiatrists is driving the market, as these treatments provide an alternative channel for patients who want effective treatment with minimal downtime.
• Combination Therapy Development: The creation of combination therapies, which involve oral and topical antifungal therapy combined, is another major innovation in the onychomycosis pharmaceutical market. This strategy is intended to treat infections more holistically by acting on the fungus through various mechanisms. Combination therapies have been demonstrated to be more effective in clinical trials and thus represent a compelling choice for patients with serious or chronic onychomycosis.
• Movement Away from Prescription Therapies: There has been a movement away from the availability of prescription-only therapies for onychomycosis. Patients are choosing to take more self-care and desire more convenient and less expensive treatment options. More patients are selecting OTC antifungal sprays, powders, and creams as convenient and affordable therapy options. This trend is contributing to the growth of the market by targeting a greater number of consumers who might not be looking for professional treatment.
• Emphasis on Pediatric and Geriatric Population: Of late, there has been an increased emphasis on treating onychomycosis in pediatric and geriatric populations, both groups that are more susceptible to fungal infections. As the population ages and fungal infections rise in children, drug manufacturers are creating safer and more effective medications specifically for these groups. This emphasis is likely to result in more targeted treatments for onychomycosis, driving market growth.

All the major trends like the release of new antifungal medicines, the increased use of laser treatments, development of combination treatments, the shift towards OTC medications, and targeting pediatric and geriatric groups are fueling tremendous growth for the onychomycosis drug market. These trends also indicate the mounting need for treatments that are better, more convenient, and specific, setting up the market to continue growing and innovating.

Strategic Growth Opportunities in the Onychomycosis Drug Market

The market for onychomycosis drugs offers a number of strategic growth opportunities as new therapies, improved patient compliance, and increasing market awareness fuel demand for successful treatments. Pharmaceutical firms can take advantage of these opportunities for growth by concentrating on high-potential areas such as new treatment development, geographic expansion, and patient-focused strategies. Following are five strategic growth opportunities in the onychomycosis drug market that offer great potential for future success.

• Over-the-Counter Expansion: With patients looking for affordable solutions to onychomycosis, expansion of OTC treatment options is a significant growth opportunity. OTC antifungal products are convenient and cheaper, enabling patients to treat their condition without a prescription. Firms that create and sell effective OTC remedies can access a huge consumer base, particularly as more individuals learn about onychomycosis and the need for early treatment. Expansion of the self-care market underpins this opportunity.
• Pediatric and Geriatric-Specific Treatment Development: The growing incidence of onychomycosis in pediatric and geriatric populations presents a valuable opportunity for growth. These populations have specific challenges, such as the demand for milder, safer therapies. Pharmaceutical firms can put their money into creating customized products for children and the elderly, filling the unmet needs of these population groups. By customizing therapy for these patient populations, firms can differentiate themselves in the competitive marketplace and gain a larger patient population.
• Penetration into Emerging Markets: Emerging markets, especially in Asia and Latin America, offer tremendous growth prospects for onychomycosis medicines. With the development of healthcare infrastructure, increased disposable incomes, and higher awareness levels about fungal infections, these markets are witnessing higher demand for effective treatments. Firms can expand their customer base by launching both prescription and OTC drugs to capture the expanding base of consumers in these markets.
• Adoption of Laser and Light-Based Therapies: Non-invasive laser and light-based therapies are the increasing trend of the onychomycosis drug market. These therapies are faster, effective treatments for the patients looking to avoid oral and topical antifungals. Pharmaceutical companies can look to associate with clinics and dermatologists for marketing these therapies and making their market position robust. Investment in laser technology and increased application can promote growth in the developed and emerging economies.
• Combination Therapy Focus: Combination therapies with both topical and oral treatments provide a high growth potential in the onychomycosis market. These therapies leverage the synergies of multiple drug classes to fight infections more efficiently and cut treatment time. Companies that design and market combination therapies can ride a rising wave of demand for quick, holistic solutions, emerging as market leaders.

Strategic opportunities for growth in the onychomycosis drug market are plentiful, most notably in segments including OTC treatment, pediatric and geriatric formulations, entering emerging markets, laser treatments, and combination therapy. Firms that take advantage of these opportunities will be poised to lead the changing market, addressing the growing need for effective and affordable onychomycosis treatment.

Onychomycosis Drug Market Driver and Challenges

The market for onychomycosis drugs is driven by a range of drivers and challenges that encompass technological advancements, regulatory barriers, economic conditions, and changing consumer needs. It is important for the stakeholders in the market to comprehend these major drivers and challenges. The market for this condition grows due to technological advancements in treatments, whereas challenges associated with cost, awareness, and regulatory approval procedures must be overcome to provide sustained progress.

The factors responsible for driving the onychomycosis drug market include:

1. Technical Advances in Drugs: Recent drug formulation advances such as more efficacious topical and oral antifungal drugs have played a leading role in contributing to the demand for onychomycosis drugs. Efinaconazole and tavaborole are such new drugs which are more target-specific and exhibit fewer side effects, enhancing better patient outcomes. With more potent treatments emerging on the market, the market for these solutions should experience greater demands.

2. Rise in Awareness and Incidence of Onychomycosis: Growing awareness regarding onychomycosis means more people are undergoing treatment for nail fungal disease. The higher incidence of the disease, especially among the older generation, is increasing demand for antifungal therapies. More widespread public health awareness campaigns along with improved accessibility to healthcare solutions are contributing towards heightened awareness that translates into diagnosis and treatment for more people afflicted by onychomycosis.

3. Increasing Demand for Non-Invasive Treatments: Patients are increasingly looking for non-invasive treatment procedures for onychomycosis, hence an increase in demand for light and laser-based treatments. These are quicker and less painful compared to other forms of treatment. The demand for these non-invasive procedures is pushing the market forward with more clinics providing the treatments.

4. Government Support and Regulatory Approvals: Government support for the development of new drugs, coupled with the approval of new treatments by regulatory bodies, has positively impacted the onychomycosis drug market. Regulatory approvals for more effective treatments are encouraging investment and increasing market competition, benefiting consumers with better treatment options.

5. Aging Geriatric Population: The global aging population is a major growth driver for the onychomycosis drugs market, with the older population being more prone to infections caused by fungi. This population trend is leading to a growth in the need for treatments, especially since elderly populations usually struggle to deal with infections because of other ailments.

Challenges in the onychomycosis drug market are:

1. Exorbitant Treatment Expenses: The price of treatments, especially newer and more potent medications, is a burden to many patients. Treatment costs can hinder access to such medications, especially in poorer countries. Pharmaceutical corporations must devise ways of lowering the cost of treatments in order to enhance accessibility and affordability.

2. Lack of Awareness in Some Areas: Although awareness of onychomycosis is increasing, most areas lack adequate education on the condition, hence delayed diagnosis and treatment. Firms must invest more in awareness programs to inform the public about the need for early detection and treatment to curb the disease burden.

3. Delays and Barriers in Regulations: The process of getting regulatory approval for new treatments and medicines is long and complicated, pushing back market entry for innovative products. Firms have to maneuver intricate regulatory environments across various markets to launch their products. Such delays can affect growth and competition within the market.

The onychomycosis pharmaceutical market is fueled by advances in drug formulations, rising awareness, and the need for non-surgical treatments. Challenges like high costs of treatment, unawareness, and regulatory challenges still affect market growth. Overcoming these challenges while taking advantage of the drivers will be instrumental in the continued growth and innovation in the market.

List of Onychomycosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies onychomycosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the onychomycosis drug companies profiled in this report include-

• Johnson & Johnson
• GSK
• Novartis
• Pfizer
• Bausch Health
• Kaken Pharmaceutical
• Galderma Bayer
• Lumenis
• Moberg Pharma
• Cipla

Onychomycosis Drug Market by Segment

The study includes a forecast for the global onychomycosis drug market by type, application, and region.

Onychomycosis Drug Market by Type [Value from 2019 to 2031]:

• Oral Medicine
• External Medicine

Onychomycosis Drug Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Onychomycosis Drug Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Onychomycosis Drug Market

The onychomycosis drug market has seen considerable progress in recent years with advancements in antifungal therapy, the growing incidence of fungal infection, and demand for potent treatments. Fungal infection of the nails known as onychomycosis has gained greater prominence due to patients' desires for more effective treatment options to treat the infection. This increased demand has promoted an increase in research and development of new medications and treatment modalities in major global markets such as the United States, China, Germany, India, and Japan.

• United States: The United States onychomycosis drug market has experienced an increase in approvals of topical and oral antifungal drugs. There has been a specific emphasis on enhancing the efficacy and convenience of these drugs. New medications such as aliconazole (Julia) and tavaborole (Kardin) have been licensed by the FDA, providing patients with more invasive and targeted solutions than conventional methods. The industry is also experiencing expansion in laser treatments and antifungal therapies available over the counter. Growing awareness of fungal infections and increased access to medical care are leading to increased demand for effective treatments for onychomycosis
• China: In China, the market for onychomycosis drugs is growing very fast as a result of increased awareness about nail fungal infections and the rise in such cases, especially among urban dwellers. Even though generic drugs control the market, new therapies, particularly topical antifungal medications, are becoming popular. The government of China has been favorable towards increasing healthcare infrastructure, indirectly supporting the market. Multinational pharmaceutical firms are also seeking collaborations to launch advanced onychomycosis drugs to address increasing demand. Market growth is further being driven by lifestyle changes and increasing health awareness among Chinese consumers.
• Germany: Germany is also a dominant player in the onychomycosis drug market in Europe. With its developed healthcare infrastructure and increasing emphasis on dermatological wellness, demand for onychomycosis therapies is growing. The market has witnessed an increase in the use of advanced topical therapy and oral drugs. An increasing trend is also observed towards the use of laser therapies and combination therapies with improved efficacy and reduced treatment time. With an aging population and increased usage of treatments for onychomycosis, Germany's market will continue to grow.
• India: India's onychomycosis pharmaceutical market is fueled by the huge population base, especially in cities, and the increasing number of individuals looking for effective treatments for fungal infections. The market is controlled by low-cost generic antifungal medications, but new treatments are gaining popularity as disposable incomes increase. Moreover, awareness campaigns and enhancing access to healthcare centers have been gaining prominence, which are driving the demand for both topical and oral treatments. The use of home remedies and traditional practices is also still strong, though pharmaceutical products are making inroads.
• Japan: Japan's onychomycosis pharmaceutical market is witnessing steady growth, with an increasing number of elderly patients being prone to fungal infections of the nails. Japan has witnessed the acceptance and growing uptake of newer, more potent antifungal drugs, such as topical and oral agents. The laser treatment of onychomycosis is also gaining ground as patients are looking for less invasive and quicker alternatives. Japan's aging population and enhanced access to healthcare translate to a higher demand for specialty treatments. The industry is projected to grow further with sustained innovations in the treatment area and an aging population.

Features of the Global Onychomycosis Drug Market

Market Size Estimates: Onychomycosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Onychomycosis drug market size by type, application, and region in terms of value ($B).

Regional Analysis: Onychomycosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the onychomycosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the onychomycosis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the onychomycosis drug market by type (oral medicine and external medicine), application (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Onychomycosis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Onychomycosis Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Onychomycosis Drug Market by Type
  • 3.3.1: Oral Medicine
  • 3.3.2: External Medicine
• 3.4: Global Onychomycosis Drug Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Onychomycosis Drug Market by Region
• 4.2: North American Onychomycosis Drug Market
  • 4.2.1: North American Market by Type: Oral Medicine and External Medicine
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Onychomycosis Drug Market
  • 4.3.1: European Market by Type: Oral Medicine and External Medicine
  • 4.3.2: European Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Onychomycosis Drug Market
  • 4.4.1: APAC Market by Type: Oral Medicine and External Medicine
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Onychomycosis Drug Market
  • 4.5.1: ROW Market by Type: Oral Medicine and External Medicine
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Onychomycosis Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Onychomycosis Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Onychomycosis Drug Market by Region
• 6.2: Emerging Trends in the Global Onychomycosis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Onychomycosis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Onychomycosis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: GSK
• 7.3: Novartis
• 7.4: Pfizer
• 7.5: Bausch Health
• 7.6: Kaken Pharmaceutical
• 7.7: Galderma Bayer
• 7.8: Lumenis
• 7.9: Moberg Pharma
• 7.10: Cipla